U.S. Infectious Respiratory Disease Diagnostics Market Size & Outlook
- Clinical Diagnostics
- In Vitro Diagnostics
- Infectious Respiratory Disease Diagnostics Market Outlook
- In Vitro Diagnostics
Global Market
Related Markets
Ask Prism AI anything about the infectious respiratory disease diagnostics market
Get a cited answer from GVR research in seconds: segment shares, growth drivers, regulation and forecast assumptions.
U.S. infectious respiratory disease diagnostics market highlights
- The U.S. infectious respiratory disease diagnostics market generated a revenue of USD 4,675.9 million in 2024 and is expected to reach USD 5,801.1 million by 2033.
- The U.S. market is expected to grow at a CAGR of 2.5% from 2025 to 2033.
- In terms of segment, reagents was the largest revenue generating product in 2024.
- Reagents is the most lucrative product segment registering the fastest growth during the forecast period.
Infectious respiratory disease diagnostics market data book summary
| Market revenue in 2024 | USD 4,675.9 million |
| Market revenue in 2033 | USD 5,801.1 million |
| Growth rate | 2.5% (CAGR from 2025 to 2033) |
| Largest segment | Reagents |
| Fastest growing segment | Reagents |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Instruments, Reagents, Services |
| Key market players worldwide | Abbott Laboratories, Thermo Fisher Scientific Inc, Koninklijke Philips NV, BD, BioMerieux SA, Bio-Rad Laboratories Inc, QuidelOrtho Corp, Siemens Healthineers AG ADR, Danaher Corp, Qiagen NV, Roche |
Other key industry trends
- In terms of revenue, U.S. accounted for 38.1% of the global infectious respiratory disease diagnostics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. infectious respiratory disease diagnostics market is projected to lead the regional market in terms of revenue in 2033.
- Canada is the fastest growing regional market in North America and is projected to reach USD 764.7 million by 2033.
The U.S. market leads the infectious respiratory disease diagnostics market due to local presence of leading players such as F. Hoffmann La Roche Ltd., Abbott, and Danaher. One of the reason for their continued dominance is the presence of well-established R&D infrastructure and favorable reimbursement policies.
Furthermore, according to the WHO, around 40,675,578 confirmed cases of COVID-19 and 653,099 deaths were reported from January 2020 to September 2021. Regular testing and diagnosis during the COVID-19 and influenza outbreak boost market growth.
In addition, regulatory and reimbursement landscape is continuously evolving to adapt to the fast-paced research progress in this sector. The U.S.FDA is developing new regulatory strategies such as Emergency Use Authorization, which is anticipated to address the urgent clinical demand and boost innovation in tests, while ensuring that the data produced by these tests is accurate and reliable.
No credit card required*
Publish Date: Jan 16, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
- Turnaround
- 5–10 working days
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Infectious Respiratory Disease Diagnostics Market Scope
Infectious Respiratory Disease Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| Koninklijke Philips NV | View profile | 73,712 | Philips Center, Amstelplein 2, Amsterdam, Netherlands, 1096 BC | www.philips.com |
| BioMerieux SA | View profile | 13,982 | Marcy l’Etoile, Lyon, France, 69280 | www.biomerieux.com |
| Siemens Healthineers AG ADR | View profile | 71,400 | Siemensstr. 3, Forchheim, BY, Germany, 91301 | www.siemens-healthineers.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Danaher Corp | View profile | 63,000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | www.danaher.com |
| QuidelOrtho Corp | View profile | 7,100 | 9975 Summers Ridge Road, San Diego, CA, United States, 92121 | www.quidelortho.com |
| Bio-Rad Laboratories Inc | View profile | 8,030 | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 | www.bio-rad.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| BD | View profile | 10001+ | Franklin Lakes, New Jersey, United States, North America | www.bd.com |
U.S. Infectious Respiratory Disease Diagnostics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Infectious Respiratory Disease Diagnostics Market Outlook will help companies and investors design strategic landscapes.
Reagents was the largest segment with a revenue share of 66.65% in 2024.
Horizon Databook has segmented the U.S. infectious respiratory disease diagnostics market based on instruments, reagents, services covering the revenue growth of each sub-segment from 2021 to 2033.
The U.S. market leads the infectious respiratory disease diagnostics market due to local presence of leading players such as F. Hoffmann La Roche Ltd., Abbott, and Danaher. One of the reason for their continued dominance is the presence of well-established R&D infrastructure and favorable reimbursement policies.
Furthermore, according to the WHO, around 40,675,578 confirmed cases of COVID-19 and 653,099 deaths were reported from January 2020 to September 2021. Regular testing and diagnosis during the COVID-19 and influenza outbreak boost market growth.
In addition, regulatory and reimbursement landscape is continuously evolving to adapt to the fast-paced research progress in this sector. The U.S.FDA is developing new regulatory strategies such as Emergency Use Authorization, which is anticipated to address the urgent clinical demand and boost innovation in tests, while ensuring that the data produced by these tests is accurate and reliable.
- U.S. Infectious Respiratory Disease Diagnostics Market Product Outlook (Revenue, USD Million , 2021-2033)
- Instruments
- Reagents
- Services
- U.S. Infectious Respiratory Disease Diagnostics Market Technology Outlook (Revenue, USD Million , 2021-2033)
- Molecular Diagnostics
- Immunoassays
- Microbiology
- Rapid/Point-of-Care Diagnostics
- Other Technologies
- U.S. Infectious Respiratory Disease Diagnostics Market Application Outlook (Revenue, USD Million , 2021-2033)
- COVID-19
- Influenza
- Tuberculosis
- Respiratory Syncytial Virus (RSV)
- Non-tuberculosis Mycobacterium Testing
- Bacterial Pneumonia Testing
- Other Respiratory Diseases
- U.S. Infectious Respiratory Disease Diagnostics Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Hospitals
- Clinics
- Diagnostics Laboratories
- Research Institutes
Reasons to subscribe to Infectious Respiratory Disease Diagnostics Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Infectious Respiratory Disease Diagnostics Market Outlook databook
- Our clientele includes a mix of Infectious Respiratory Disease Diagnostics Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Infectious Respiratory Disease Diagnostics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Infectious Respiratory Disease Diagnostics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.S. Infectious Respiratory Disease Diagnostics Market, 2021-2033 (US$M)
US Product - Infectious Respiratory Disease Diagnostics Market Statistics, 2024 - 2033 (US$M)
